On 9 June 2010, orphan designation (EU/3/10/750) was granted by the European Commission to Sanofi-Aventis, France, for rifapentine for the treatment of tuberculosis.
In October 2012, Sanofi-Aventis changed name to Sanofi-Aventis Groupe.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of tuberculosis
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.